Literature DB >> 28055379

Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.

Nyam-Osor Chimge1,2, Sara Ahmed-Alnassar2,3, Baruch Frenkel2,3,4.   

Abstract

RUNX1 plays opposing roles in breast cancer: a tumor suppressor in estrogen receptor-positive (ER+) disease and an oncogenic role in ER-negative (ER-) tumors. Potentially mediating the former, we have recently reported that RUNX1 prevents estrogen-driven suppression of the mRNA encoding the tumor suppressor AXIN1. Accordingly, AXIN1 protein expression was diminished upon RUNX1 silencing in ER+ breast cancer cells and was positively correlated with AXIN1 protein expression across tumors with high levels of ER. Here we report the surprising observation that RUNX1 and AXIN1 proteins are strongly correlated in ER- tumors as well. However, this correlation is not attributable to regulation of AXIN1 by RUNX1 or vice versa. The unexpected correlation between RUNX1, playing an oncogenic role in ER- breast cancer, and AXIN1, a well-established tumor suppressor hub, may be related to a high ratio between the expression of variant 2 and variant 1 (v2/v1) of AXIN1 in ER- compared with ER+ breast cancer. Although both isoforms are similarly regulated by RUNX1 in estrogen-stimulated ER+ breast cancer cells, the higher v2/v1 ratio in ER- disease is expected to weaken the tumor suppressor activity of AXIN1 in these tumors.

Entities:  

Keywords:  AXIN1 alternative splicing; oncogene; tumor suppressor

Mesh:

Substances:

Year:  2017        PMID: 28055379      PMCID: PMC5324758          DOI: 10.1080/15384101.2016.1237325

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  61 in total

1.  Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex.

Authors:  Vivian S W Li; Ser Sue Ng; Paul J Boersema; Teck Y Low; Wouter R Karthaus; Jan P Gerlach; Shabaz Mohammed; Albert J R Heck; Madelon M Maurice; Tokameh Mahmoudi; Hans Clevers
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

2.  Runx2 in normal tissues and cancer cells: A developing story.

Authors:  Karen Blyth; Francois Vaillant; Alma Jenkins; Laura McDonald; Marie Anne Pringle; Camille Huser; Torsten Stein; James Neil; Ewan R Cameron
Journal:  Blood Cells Mol Dis       Date:  2010-06-26       Impact factor: 3.039

Review 3.  The links between axin and carcinogenesis.

Authors:  S Salahshor; J R Woodgett
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 4.  RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.

Authors:  James K Mangan; Nancy A Speck
Journal:  Crit Rev Oncog       Date:  2011

5.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

Review 6.  Lapatinib in the treatment of breast cancer.

Authors:  Gerald M Higa; Jame Abraham
Journal:  Expert Rev Anticancer Ther       Date:  2007-09       Impact factor: 4.512

7.  Runx1 promotes B-cell survival and lymphoma development.

Authors:  Karen Blyth; Nicholas Slater; Linda Hanlon; Margaret Bell; Nancy Mackay; Monica Stewart; James C Neil; Ewan R Cameron
Journal:  Blood Cells Mol Dis       Date:  2009-03-09       Impact factor: 3.039

8.  The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc.

Authors:  Hugh K Arnold; Xiaoli Zhang; Colin J Daniel; Deanne Tibbitts; Julie Escamilla-Powers; Amy Farrell; Sara Tokarz; Charlie Morgan; Rosalie C Sears
Journal:  EMBO J       Date:  2009-01-08       Impact factor: 11.598

9.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

10.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more
  9 in total

1.  Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation.

Authors:  Yuanyuan Nie; Lei Zhou; Hong Wang; Naifei Chen; Lin Jia; Cong Wang; Yichen Wang; Jingcheng Chen; Xue Wen; Chao Niu; Hui Li; Rui Guo; Songling Zhang; Jiuwei Cui; Andrew R Hoffman; Ji-Fan Hu; Wei Li
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

2.  Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.

Authors:  Elena Alexandrova; Giorgio Giurato; Pasquale Saggese; Giovanni Pecoraro; Jessica Lamberti; Maria Ravo; Francesca Rizzo; Domenico Rocco; Roberta Tarallo; Tuula A Nyman; Francesca Collina; Monica Cantile; Maurizio Di Bonito; Gerardo Botti; Giovanni Nassa; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2019-12-02       Impact factor: 5.911

3.  Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Authors:  Nandini Dey; Amy Krie; Jessica Klein; Kirstin Williams; Amanda McMillan; Rachel Elsey; Yuliang Sun; Casey Williams; Pradip De; Brian Leyland-Jones
Journal:  Int J Mol Sci       Date:  2017-06-07       Impact factor: 5.923

4.  Association between AXIN1 Gene Polymorphisms and Bladder Cancer in Chinese Han Population.

Authors:  Qin Li; Peng Zhang; Yanyun Wang; Yan Zhang; Kai Li; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Dis Markers       Date:  2019-04-15       Impact factor: 3.434

5.  A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells.

Authors:  Ran Ran; Hannah Harrison; Nur Syamimi Ariffin; Rahna Ayub; Henry J Pegg; Wensheng Deng; Andrea Mastro; Penny D Ottewell; Susan M Mason; Karen Blyth; Ingunn Holen; Paul Shore
Journal:  Oncogene       Date:  2020-01-31       Impact factor: 9.867

6.  HCV-Associated Exosomes Upregulate RUNXOR and RUNX1 Expressions to Promote MDSC Expansion and Suppressive Functions through STAT3-miR124 Axis.

Authors:  Bal Krishna Chand Thakuri; Jinyu Zhang; Juan Zhao; Lam N Nguyen; Lam N T Nguyen; Madison Schank; Sushant Khanal; Xindi Dang; Dechao Cao; Zeyuan Lu; Xiao Y Wu; Yong Jiang; Mohamed El Gazzar; Shunbin Ning; Ling Wang; Jonathan P Moorman; Zhi Q Yao
Journal:  Cells       Date:  2020-12-18       Impact factor: 6.600

7.  Age-related DNA methylation in paired normal and tumour breast tissue in Chinese breast cancer patients.

Authors:  Maeve Kiely; Lap Ah Tse; Hela Koka; Difei Wang; Priscilla Lee; Feng Wang; Cherry Wu; Koon Ho Tsang; Wing-Cheong Chan; Sze Hong Law; Han Zhang; Eric Karlins; Bin Zhu; Amy Hutchinson; Belynda Hicks; Bin Zhu; Xiaohong R Yang
Journal:  Epigenetics       Date:  2020-09-24       Impact factor: 4.528

8.  Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ.

Authors:  Tong Zhou; Maocai Luo; Wei Cai; Siyuan Zhou; Danying Feng; Chundi Xu; Hongyan Wang
Journal:  EBioMedicine       Date:  2018-05-11       Impact factor: 8.143

Review 9.  Complex Interplay between the RUNX Transcription Factors and Wnt/β-Catenin Pathway in Cancer: A Tango in the Night.

Authors:  Kerri Sweeney; Ewan R Cameron; Karen Blyth
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.